•
All Products
Chapter 9 — Specialist Care, Affordability and Treatment Acceptance

Preventative dentistry is about retention. Specialist dentistry is about decisions. The economics are fundamentally different. A patient does not need much persuasion to attend a hygiene appointment. A patient does need persuasion to spend £3,000, £4,000 or £5,000 on treatment.
This is particularly true for Invisalign, clear aligners and implants. These are often the treatments that transform a dental practice's economics. But they are also the treatments that require patients to make significant financial commitments.
The Biggest Barrier Is Not Awareness
Many dental practices assume specialist growth comes from marketing. The assumption is simple. More marketing creates more enquiries. More enquiries create more consultations. More consultations create more treatment starts.
The reality is more complicated. Patients already know these treatments exist. Most adults know they can straighten their teeth. Most patients who have lost a tooth know implants are available. The challenge is not awareness. The challenge is commitment.
Patients delay treatment for years because they struggle to justify the expense. Not because they do not understand the treatment.
Trust Matters More Than Marketing
This creates an uncomfortable truth. The highest-converting Invisalign and implant patients are often existing patients. Not new ones. When patients spend £3,000 or more, they usually choose someone they trust.
That trust is built over years. Regular check-ups. Hygiene appointments. Restorative work. Conversations with clinicians. This is one reason why the earlier chapters matter so much. Memberships. Retention. Attendance. Relationships. These are not separate topics. They are the foundation of specialist conversion.
A patient who has trusted the practice for five years is significantly easier to convert than a patient arriving from a Google advertisement yesterday.
The Number That Decides Everything: Starts Per 100 Patients
This chapter argues that specialist care carries the economics of the practice. It is worth stating the measure that determines whether it can.
Specialist starts per 100 active patients per year is the single metric that decides whether £300 per chair hour is reachable. Most practices do not know theirs. It should be reported monthly, split by age cohort and by length of relationship with the practice.
The tenure split is the important one. If starts per 100 rise with years of membership, the trust mechanism described above is real and can be managed. If the curve is flat, what looks like a trust effect is selection — the practice is attracting patients who were going to proceed anyway. This is the measurement that Chapter 8 defers to, and no practice can design a membership strategy around specialist conversion without it.
There is also a demographic ceiling that no amount of execution overcomes. Clear aligners address roughly the 18–49 population; implants address roughly the 50-plus. A patient base heavily skewed to either end has a natural limit on achievable starts, and practices should establish that limit before setting targets against it.
Specialist Marketing Is Different
This does not mean marketing has no role. It does. But specialist marketing works differently. The purpose is not necessarily to convince someone they need treatment. The purpose is to create curiosity and consideration. This is particularly visible in Invisalign. The most successful providers do not market orthodontics.
They market outcomes. Confidence. Appearance. Lifestyle. The treatment itself becomes secondary. Implants follow a similar pattern. Patients are rarely excited about implants. They are excited about replacing a missing tooth. Eating normally again. Smiling confidently again.
The treatment is simply the mechanism.
Finance Is The Most Powerful Marketing Tool
This is where many practices misunderstand specialist growth. The highest-return marketing investment is often not another advertising campaign. It is patient finance.
Patient finance directly addresses the biggest obstacle standing between treatment recommendation and treatment start. Affordability. A patient who hesitates at £3,000 may not hesitate at £125 per month.
The treatment has not changed. The clinician has not changed. The outcome has not changed. Only the payment structure has changed. Yet the patient's decision changes dramatically.
Patients Think In Monthly Budgets
This behaviour is remarkably consistent. Across more than one million completed finance applications, the vast majority of patients select repayment amounts that fit comfortably within discretionary monthly spending.
The sweet spot is surprisingly narrow. Most patients ultimately choose monthly payments between approximately £75 and £200. The majority of funded treatments fall within this range. Beyond £200 per month, conversion begins to weaken. Beyond £250 per month, the pool of willing consumers becomes substantially smaller.
This matters enormously when presenting treatment options. Practices often communicate treatment prices in total cost. Patients frequently make decisions in monthly affordability. The two are not the same.
The Cost Of A Member Discount
Practices frequently consider offering plan members a percentage discount on specialist treatment. The arithmetic deserves care, because it is less forgiving than it appears.
A 10% discount on a £3,000 case is £300 — more than a full year of plan fees at most price points, given away in a single transaction. And because the discount comes off gross margin rather than revenue, break-even is worse than the headline. Where variable costs run around £700 a case, a 10% discount requires roughly 15% more starts simply to stand still. A 20% discount requires roughly 35% more.
Set against the demographic ceiling described earlier, that is a demanding threshold. Three design rules follow. Vest the discount after a period of continuous membership rather than granting it at signup, or the offer will be gamed. Cap it in absolute terms, or implant cases become very expensive very quickly. And gate its depth on length of membership rather than on attendance frequency — frequency gating rewards patients whose frequent attendance is clinically indicated, who are typically the least likely aligner candidates.
Above all, launch it against a control group. Rolled out everywhere at once, the effect of a discount cannot be separated from seasonality, a new treatment coordinator or a marketing campaign, and the practice will never learn whether it worked.
The Wrong Way To Present Treatment
Many practices still follow a traditional treatment presentation. The clinician explains the treatment. The treatment plan is printed. The total cost is presented. Only when hesitation appears does finance enter the conversation.
By that point, the patient has already started saying no. Finance becomes a rescue attempt. Not a decision tool. This is one of the biggest mistakes in specialist dentistry. Finance should not be introduced after resistance. It should be introduced alongside the treatment recommendation.
The patient should understand both the clinical outcome and the affordability options simultaneously.
The Role Of Invisalign And Implants
The economics of a high-performing practice depend heavily on these categories. Earlier chapters demonstrated that specialist care contributes a disproportionate share of revenue relative to chair time. This is particularly true for:
Invisalign and clear aligners
Single-tooth implants
Implant-retained restorative work
These treatments often generate £1,000 or more of revenue per clinical hour. Very few other treatments can achieve similar economics consistently. The challenge therefore is not clinical capability. The challenge is creating enough treatment starts.
Why Open Days Work
One of the clearest examples of this principle is the Invisalign open day. During an open day, practices become highly focused. Marketing is concentrated. Pricing is clear. Finance is visible. Treatment coordinators are engaged. Clinicians are aligned. The process becomes simple. Conversion rates often increase dramatically.
What makes this interesting is not the event itself. It is what the event reveals. Practices already know how to convert specialist treatment. They simply do not operate that way every day. The open day removes friction. The lesson is not to run more open days. The lesson is to make everyday specialist conversion look more like an open day.
Marketing Should Support Affordability
Most specialist marketing eventually converges on the same idea. Patients want to know:
What is the treatment?
What will it achieve?
How much will it cost?
Can I afford it?
The final question often determines whether treatment starts. This is why affordability should sit at the centre of specialist growth strategies. Not at the end. Not as an afterthought. And not only after a patient hesitates.
The Real Insight
Most practices believe specialist growth comes from generating more enquiries. The highest-performing practices think differently. They focus on treatment acceptance. They focus on affordability. They focus on finance.
Because once the patient is already sitting in the chair, there are very few investments that produce a higher return than helping that patient start treatment today.
The most effective specialist marketing tool is often not another advertisement. It is making treatment affordable.